In search for next-gen Covid treat­ment, Pfiz­er taps tiny biotech for re­search deal

Pfiz­er has inked a deal to de­vel­op a new Covid ther­a­py with Clear Creek Bio — a 10-per­son biotech out of RA Cap­i­tal with an of­fice in Cam­bridge, MA, but one that op­er­ates ful­ly re­mote­ly.

Paxlovid has be­come a big mon­ey­mak­er for Pfiz­er this year, pro­ject­ing $22 bil­lion in sales on the year. But the Big Phar­ma has be­gun its search for a next-gen­er­a­tion Covid an­tivi­ral and po­ten­tial com­bi­na­tion ther­a­pies as sup­ply of Paxlovid great­ly eclipses ac­tu­al use of the an­tivi­ral.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER